Defective Medication and Products
Defective Medication, products and Recall Attorneys serving Las Vegas and all of Nevada
At Seegmiller and Associates, we have many years of experience handling Nevada medication and defective product cases. Our experienced pharmaceutical litigation attorneys have handled cases focused on all types of pharmaceutical medications both that have been recalled and that are still on the market.
If you have been injured by a pharmaceutical drug because the drug company did not fulfill its duties, properly warn of the risks or marketed for non-approved treatments, you may be eligible for compensation. For more information about pharmaceutical litigation and other personal injury claims, please visit our frequently asked questions pages or contact us and one of our specialists will evaluate your claim.
Some of our pharmaceutical medication recall litigation that we are handling in Las Vegas Nevada
Yaz, Yasmin®, Ocella
Yaz, Yasmin® and the generic Ocella are birth control pills. The difference between these birth control pills and others is that they contain drosperinone. Drosperinone affects the body’s normal regulation of the potassium levels in the blood. If the level of potassium is abnormal it can cause blood blots, heart attacks, strokes, pulmonary embolisms, deep vein thrombosis, or sudden death.
Chantix®
Chantix®, manufactured by Pfizer, is a perscription, anti-smoking drug. There have been very serious side effects connected with the use of Chantix®. These side effects include severe depression, suicide, attempted suicide, self destructive behavior, blackouts or loss of consciousness. As of July 2009, the FDA required Pfizer to include a black box warning on its labeling for Chantix. The FDA requires a black box warning when medical studies indicate that the drug carries a significant risk of serious or even life-threatening side-effects.
Avandia® and heart attacks
Avandia® is an oral prescription medication used in treating type 2 diabetes. The FDA issued a safety alert dated May 21, 2007, stating, “Safety data from controlled clinical trials have shown that there is potentially significant increased risk of heart attack and heart-related deaths in patients taking Avandia.”
Pain pump usage and cartilage damage
A recent study published in 2008 by the American Journal of Sports Medicine identified intra-articular or post-operative pain pumps as a likely cause of a specific type of chondrolysis called Postarthritic Glenohumeral Chondrolyisis. Chondrolysis is the destruction and deterioration of joint cartilage. This type of chrondolysis is specifically associated with use of pain pumps following shoulder surgery.
Fosamax® and Bone decay
In a study recently released by the University of British Columbia and published in the Journal of Rheumatology on January 15, 2008, a link has been established between popular osteoporosis drugs and bone necrosis. Bone necrosis is a disease that leads to a permanent loss of blood supply to the bones. Without an adequate blood supply the bone tissue dies and causes the bone to collapse.
A University of British Columbia and Vancouver Coastal Health Research Institute study has found that t popular class of osteoporosis drugs which includes Fosamax® nearly triples the risk of developing bone necrosis, a condition that can lead to disfigurement and incapacitating pain.
The irony is that Fosamax® was originally prescribed to prevent bone decay but instead may actually cause decay of certain bones which can potentially lead to fractures.
Digitek® and Cardiac Problems
Digitek®, a drug widely used in the treatment of various heart conditions was recalled in early 2008 after the medication was found to contain twice the appropriate level of the active ingredient, digoxin. Because patients taking Digitek® are already under a physician’s care for heart problems, an incorrect dosage of this medication can be especially dangerous secreting even more cardiac instability and compounding existing problems.
Defective Defibrillator Cardiac Leads
Defibrillators are implanted in patients who are at risk of sudden cardiac arrest. The leads extend from the defibrillator to the heart and deliver an electrical shock or rapid pacing directly to the heart so that the heard can be restored to a normal rhythm. On October 15, 2007, reports of fatalities due to factures of the lead wires causing the defibrillator to emit a massive and painful shock to the heart resulted in Medtronic suspending the sale of their Sprint Fidelis leads, model nos. 6930, 6931, 6948, and 6949.
Additional Defective Drugs
Many defective drugs have an existing litigation history, meaning that multiple victims have filed claims for similar injuries. There will, however, always be a first claim against a dangerous or defective drug, which often paves the way for others who have been injured and previously chose to remain silent. It is possible that your case could be the first of its kind, or that others have filed similar suits against the manufacturer. Learn more about additional defective drug claims filed by our pharmaceutical litigation attorneys.
Comments on this entry are closed.